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OBJECTIVE — To characterize the cardiovascular risk proﬁle of subjects categorized differ-
ently by A1C- and oral glucose tolerance test (OGTT)-based diagnostic criteria for diabetes
according to the recommendations of the American Diabetes Association (ADA).
RESEARCH DESIGN AND METHODS — An OGTT, A1C, and several cardiovascular
risk factors were assessed in 964 individuals without known diabetes participating in a cross-
sectional epidemiological survey in Gran Canaria, Spain.
RESULTS — Taking the OGTT as the gold standard, the sensitivity and speciﬁcity of an A1C
value 6.5% were 38.7 and 99.6%, respectively. Subjects who fulﬁlled A1C-based criterion
presented greater measures of BMI and waist circumference, lower values for HDL cholesterol,
andhighervaluesforfastingplasmaglucose,homeostasismodelassessmentofinsulinresistance,
and ﬁbrinogen than subjects with diabetic OGTT but A1C 6.5%.
CONCLUSIONS — Newly diagnosed diabetic individuals who fulﬁll A1C-based diagnostic
criterion for the disease display a more unfavorable cardiovascular risk proﬁle than individuals
who only meet the glucose-based criteria.
Diabetes Care 33:2671–2673, 2010
L
ast year, an International Expert
CommitteeadvocatedtheuseofA1C
testing for the diagnosis of diabetes
(1). Based on the correlation between
A1C levels and risk of retinopathy in sev-
eral epidemiological studies, the commit-
tee determined that an A1C value 6.5%
should be used as the diagnostic thresh-
old. Guided by this report, the American
DiabetesAssociation(ADA)hasapproved
the use of A1C as an additional criterion
for diagnosing type 2 diabetes (2).
Increasing evidence, however, dem-
onstrates a low level of agreement be-
tween a diabetes diagnosis made by A1C
and one obtained using conventional cri-
teria based on plasma glucose (3–7). As
stressed by the ADA, the characterization
of subjects discordantly categorized by
bothtestsisnowpending(2).Thepresent
report targeted the assessment of differ-
ences in the cardiovascular risk proﬁles
of subjects categorized differently as
having or not having diabetes with di-
agnostic criteria based on plasma glu-
cose and A1C.
RESEARCH DESIGN AND
METHODS— The Telde Study is a
cross-sectional population-based sur-
vey conducted in Telde, a city located
on the island of Gran Canaria, Canary
Islands, Spain. The present study was
carried out on the 964 participants (at
least 30 years of age) without a previous
diagnosis of diabetes. The design and
conduct of the survey have been previ-
ously described (8).
A1C was determined using high-
performanceliquidchromatographywith
an HA-8140 analyzer (Menarini Diagnos-
tics-Arkray, Kyoto, Japan) calibrated to
theJapaneseDiabetesSocietyandtheJap-
aneseSocietyforClinicalChemistry(JDS/
JSCC) system. Realignment to the U.S.
National Glycohemoglobin Standardiza-
tion Program (NGSP) values was done
according to a national consensus docu-
ment for the harmonization of A1C in
Spain (9) using the following formula:
NGSP (%)  0.985  JDS/JSCC (%) 
0.46. Participants were categorized ac-
cording to the results of fasting and 2-h
plasma glucose from a standard 75-g oral
glucose tolerance test (OGTT) (diabetes
or no diabetes) and A1C levels (6.5 or
6.5%) (2). The metabolic syndrome
was deﬁned according to the joint state-
ment recently proposed by a number of
professional organizations (10). Insulin
resistance and pancreatic -cell function
were estimated using the homeostasis
model assessment for insulin resistance
(HOMA-IR) and the HOMA for -cell,
respectively.
Statistical analyses
Age- and sex-adjusted percentages and
means were obtained using logistic re-
gression and ANCOVA, respectively.
When necessary, logarithmical transfor-
mation was performed to reduce skew-
ness, and values were expressed as
geometric means. Percentages and means
were compared using the likelihood ratio
test and the F test, respectively, and ho-
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signiﬁcant differences were found by us-
ing the corresponding linear contrasts.
Multiple backward stepwise logistic re-
gression analysis was used to investigate
independent effects of associated factors
with A1C 6.5%.
RESULTS— Sixty-two subjects were
diagnosed with diabetes according to the
OGTTresults(35withfastingglucose7
mmol/l and the remaining 27 only by 2-h
glucose). Twenty-eight subjects pre-
sented an A1C value 6.5%, 24 of whom
alsohaddiabetesusingtheOGTTcriteria.
Thus, the diagnosis of diabetes based on
an A1C 6.5% yielded a sensitivity of
38.7% and a speciﬁcity of 99.6%. The
agreement between the glucose- and
A1C-based criteria for diagnosis was
moderate ( statistic  0.51; 95% CI
[0.387–0.641]).Table1presentstheage-
and sex-adjusted measures of a set of car-
diovascular risk factors and indirect indi-
cators of insulin resistance and insulin
secretion according to A1C- and glucose-
based diagnosis of diabetes.
As expected, individuals classiﬁed as
nondiabetic by both diagnostic methods
showedthemostfavorablecardiovascular
risk proﬁle. By contrast, the group meet-
ing A1C diabetes criteria presented
greater measures of BMI and waist cir-
cumference, lower values of HDL choles-
terol, and higher values of fasting plasma
glucose, ﬁbrinogen, and HOMA-IR than
the group fulﬁlling only the glucose-
based criteria. Multivariate logistic
regression analysis demonstrated that ab-
dominal obesity (dichotomized with the
cutoff for diagnosis of the metabolic syn-
drome) and 2-h plasma glucose were the
only variables independently associated
with an A1C value 6.5%.
CONCLUSIONS— Several recent
studies have compared A1C and OGTT
for the detection of undiagnosed diabetes
among the participants in different epide-
miological surveys. While notable diver-
gences have been found across ethnic
groups (6), our ﬁndings are in agreement
with those observed in other Caucasian-
majority populations (3–6) and conﬁrm
that,consideredinisolation,A1Cisavery
speciﬁc but too insensitive method of di-
agnosing diabetes.
On the other hand, although differ-
ences were not observed for other
cardiovascular risk factors, such as hy-
pertension, metabolic syndrome, or ele-
vation of C-reactive protein, the present
data show that individuals who met the
A1Ccriterionfordiabeteswerecharacter-
izedbygreatermeasuresofBMIandwaist
circumference; higher values of fasting
glucose, HOMA-IR, and ﬁbrinogen; and
lower values of HDL cholesterol than
individuals fulﬁlling only the OGTT di-
agnostic criteria. These results in sub-
jects with newly diagnosed diabetes
expand previous data that have re-
lated the A1C measurement to the met-
abolic syndrome and several markers of
systemic inﬂammation and disturbed
hemostasis among the nondiabetic pop-
ulation (11–13). In fact, abdominal
obesity was one of the only two vari-
ables that were independently associ-
ated with an A1C value 6.5% in our
multivariate regression model. The sec-
Table 1—Age- and sex-adjusted cardiovascular risk factors and measures of insulin resistance and insulin secretion according to diagnosis of
diabetes based on OGTT and A1C
Group 1
(A1C 6.5%)
Group 2
(OGTT /A1C 6.5%)
Group 3
(OGTT /A1C 6.5%)
n 28 38 898 P
Age (years) 54.8 (10.9)
a 58.5 (10.9)
a 46.4 (11.3)
b 0.001
Men/women (%) 67.9/32.1
a 60.5/39.5
a 41.5/58.5
b 0.002
BMI (kg/m
2) 30.7 (0.9)
a 28.2 (0.78)
b 27.9 (0.16)
b 0.009
Waist (cm) 105.4 (2.2)
a 99.0 (1.9)
b 96.2 (0.4)
b 0.001
Systolic blood pressure (mmHg) 127.3 (2.6)
a 124.2 (2.3)
a 117.2 (0.47)
b 0.001
Diastolic blood pressure (mmHg) 79.4 (1.9)
a 75.2 (1.7)
a,b 72.8 (0.3)
b 0.001
Hypertension (%) 34.7 (10.3) 34.0 (9.0) 24.9 (2.0) 0.290
Smoking (%) 22.8 (11.7) 13.0 (13.4) 24.8 (2.0) 0.269
Glucose (mmol/l)* 8.12 (0.20)
a 6.32 (0.16)
b 4.98 (3.2)
c 0.001
2-h glucose (mmol/l)* 11.43 (0.75)
a 10.4 (0.4)
a 5.5 (0.08)
b 0.001
A1C (%)* 7.47 (0.11)
a 5.61 (0.08)
b 5.29 (1.5)
c 0.001
Cholesterol (mmol/l) 5.35 (0.18) 5.56 (0.16) 5.49 (0.03) 0.646
HDL cholesterol (mmol/l) 1.24 (0.06)
a 1.41 (0.05)
b 1.40 (0.01)
b 0.018
Triglycerides (mmol/l)* 1.40 (0.13)
a 1.40 (0.10)
a 1.16 (0.02)
b 0.018
LDL cholesterol (mmol/l) 3.38 (0.16) 3.48 (0.14) 3.48 (0.03) 0.840
CRP 1 mg/l (%) 20.2 (12.0)
a 7.1 (15.7)
a,b 3.3 (4.7)
b 0.003†
PAI-1 (ng/ml) 40.5 (3.35)
a 32.2 (2.9)
a,b 27.7 (0.6)
b 0.001
Fibrinogen (mg/dl) 3.56 (0.12)
a 3.21 (0.11)
b 3.16 (0.02)
b 0.005
Von Willebrand factor (IU/l) 126.0 (6.8)
a 116.3 (5.9)
a,b 106.1 (1.2)
b 0.006
Homocysteine (	mol/l)* 10.9 (0.79) 10.7 (0.67) 10.6 (0.13) 0.916
Metabolic syndrome (%) 82.1 (13.7)
a 60.6 (9.3)
a 23.6 (2.2)
b 0.001‡
Insulin (pmol/l)* 90.38 (11.48)
a 76.05 (7.89)
a 48.79 (1.43)
b 0.001
HOMA-IR* 4.54 (0.61)
a 2.98 (0.32)
b 1.49 (0.06)
c 0.001
HOMA-* 24.9 (3.61) 29.2 (3.12) 23.1 (0.63) 0.178
Values are expressed as percentages and arithmetic or geometric* means (SE). Values followed by the same letter do not differ statistically. †OR (95% CI) group 1
vs. group 3: 7.4 (2.7–20.4). ‡OR (95% CI) group 1 vs. group 3: 14.8 (5.0–44.0) and group 2 vs. group 3: 5.0 (2.4–10.5). CRP, C-reactive protein. PAI-1,
plasminogen activator inhibitor 1.
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which displaced fasting plasma glucose
from the model. This ﬁnding indicates
that the presence of A1C levels 6.5%
in this subset of individuals without a
previous diagnosis of diabetes depends
more on postprandial plasma glucose
than on basal glucose. A greater contri-
bution of postprandial versus fasting
glucose to A1C levels has been simi-
larly observed among subjects with es-
tablished diabetes and moderately
increased levels of A1C (14). The par-
ticular inﬂuence of postprandial glu-
cose, a well established cardiovascular
risk factor (15), on A1C levels could re-
inforce the role of A1C as a potential
marker of cardiovascular risk.
Accepting the limitations inherent to
this small cross-sectional study, these
ﬁndings could suggest the following: are
individualsintheearlystagesofdiagnosis
who meet the A1C criteria for diabetes
more insulin resistant and display a more
unfavorable cardiovascular risk proﬁle
than those who fulﬁll only the OGTT-
based criteria? Prospective studies focus-
ing on this question will be needed to
examine this possibility.
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